China Biosimilar Monoclonal Antibodies Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 Biosimilar Monoclonal Antibodies Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 China Biosimilar Monoclonal Antibodies Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 China Biosimilar Monoclonal Antibodies Overall Market Size
2.1 China Biosimilar Monoclonal Antibodies Market Size: 2021 VS 2027
2.2 China Biosimilar Monoclonal Antibodies Revenue, Prospects & Forecasts: 2016-2027
2.3 China Biosimilar Monoclonal Antibodies Sales: 2016-2027
3 Company Landscape
3.1 Top Biosimilar Monoclonal Antibodies Players in China Market
3.2 Top China Biosimilar Monoclonal Antibodies Companies Ranked by Revenue
3.3 China Biosimilar Monoclonal Antibodies Revenue by Companies
3.4 China Biosimilar Monoclonal Antibodies Sales by Companies
3.5 China Biosimilar Monoclonal Antibodies Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Biosimilar Monoclonal Antibodies Companies in China Market, by Revenue in 2020
3.7 Manufacturers Biosimilar Monoclonal Antibodies Product Type
3.8 Tier 1, Tier 2 and Tier 3 Biosimilar Monoclonal Antibodies Players in China Market
3.8.1 List of Tier 1 Biosimilar Monoclonal Antibodies Companies in China
3.8.2 List of Tier 2 and Tier 3 Biosimilar Monoclonal Antibodies Companies in China
4 Sights by Type
4.1 Overview
4.1.1 By Type - China Biosimilar Monoclonal Antibodies Market Size Markets, 2021 & 2027
4.1.2 Infliximab
4.1.3 Rituximab
4.1.4 Trastuzumab
4.1.5 Adalimumab
4.1.6 Other
4.2 By Type - China Biosimilar Monoclonal Antibodies Revenue & Forecasts
4.2.1 By Type - China Biosimilar Monoclonal Antibodies Revenue, 2016-2021
4.2.2 By Type - China Biosimilar Monoclonal Antibodies Revenue, 2022-2027
4.2.3 By Type - China Biosimilar Monoclonal Antibodies Revenue Market Share, 2016-2027
4.3 By Type - China Biosimilar Monoclonal Antibodies Sales & Forecasts
4.3.1 By Type - China Biosimilar Monoclonal Antibodies Sales, 2016-2021
4.3.2 By Type - China Biosimilar Monoclonal Antibodies Sales, 2022-2027
4.3.3 By Type - China Biosimilar Monoclonal Antibodies Sales Market Share, 2016-2027
4.4 By Type - China Biosimilar Monoclonal Antibodies Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - China Biosimilar Monoclonal Antibodies Market Size, 2021 & 2027
5.1.2 Oncology
5.1.3 Autoimmune Disease
5.1.4 Other
5.2 By Application - China Biosimilar Monoclonal Antibodies Revenue & Forecasts
5.2.1 By Application - China Biosimilar Monoclonal Antibodies Revenue, 2016-2021
5.2.2 By Application - China Biosimilar Monoclonal Antibodies Revenue, 2022-2027
5.2.3 By Application - China Biosimilar Monoclonal Antibodies Revenue Market Share, 2016-2027
5.3 By Application - China Biosimilar Monoclonal Antibodies Sales & Forecasts
5.3.1 By Application - China Biosimilar Monoclonal Antibodies Sales, 2016-2021
5.3.2 By Application - China Biosimilar Monoclonal Antibodies Sales, 2022-2027
5.3.3 By Application - China Biosimilar Monoclonal Antibodies Sales Market Share, 2016-2027
5.4 By Application - China Biosimilar Monoclonal Antibodies Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 Celltrion
6.1.1 Celltrion Corporation Information
6.1.2 Celltrion Overview
6.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Description
6.1.5 Celltrion Recent Developments
6.2 Pfizer (Hospira)
6.2.1 Pfizer (Hospira) Corporation Information
6.2.2 Pfizer (Hospira) Overview
6.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Description
6.2.5 Pfizer (Hospira) Recent Developments
6.3 3SBIO
6.3.1 3SBIO Corporation Information
6.3.2 3SBIO Overview
6.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Description
6.3.5 3SBIO Recent Developments
6.4 Novartis (Sandoz)
6.4.1 Novartis (Sandoz) Corporation Information
6.4.2 Novartis (Sandoz) Overview
6.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Description
6.4.5 Novartis (Sandoz) Recent Developments
6.5 Dr Reddy's
6.5.1 Dr Reddy's Corporation Information
6.5.2 Dr Reddy's Overview
6.5.3 Dr Reddy's Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.5.4 Dr Reddy's Biosimilar Monoclonal Antibodies Product Description
6.5.5 Dr Reddy's Recent Developments
6.6 Celgen Biopharma
6.6.1 Celgen Biopharma Corporation Information
6.6.2 Celgen Biopharma Overview
6.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Description
6.6.5 Celgen Biopharma Recent Developments
6.7 Cadila Healthcare
6.7.1 Cadila Healthcare Corporation Information
6.7.2 Cadila Healthcare Overview
6.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Description
6.7.5 Cadila Healthcare Recent Developments
6.8 Hisun Pharma
6.8.1 Hisun Pharma Corporation Information
6.8.2 Hisun Pharma Overview
6.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Description
6.8.5 Hisun Pharma Recent Developments
6.9 Torrent Pharmaceuticals
6.9.1 Torrent Pharmaceuticals Corporation Information
6.9.2 Torrent Pharmaceuticals Overview
6.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales and Revenue in China Market (2016-2021)
6.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Description
6.9.5 Torrent Pharmaceuticals Recent Developments
7 China Biosimilar Monoclonal Antibodies Production Capacity, Analysis
7.1 China Biosimilar Monoclonal Antibodies Production Capacity, 2016-2027
7.2 Biosimilar Monoclonal Antibodies Production Capacity of Key Manufacturers in China Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Biosimilar Monoclonal Antibodies Supply Chain Analysis
9.1 Biosimilar Monoclonal Antibodies Industry Value Chain
9.2 Biosimilar Monoclonal Antibodies Upstream Market
9.3 Biosimilar Monoclonal Antibodies Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Biosimilar Monoclonal Antibodies Distributors and Sales Agents in China Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of TablesTable 1. Key Players of Biosimilar Monoclonal Antibodies in China Market
Table 2. Top Biosimilar Monoclonal Antibodies Players in China Market, Ranking by Revenue (2019)
Table 3. China Biosimilar Monoclonal Antibodies Revenue by Companies, (US$, Mn), 2016-2021
Table 4. China Biosimilar Monoclonal Antibodies Revenue Share by Companies, 2016-2021
Table 5. China Biosimilar Monoclonal Antibodies Sales by Companies, (K Units), 2016-2021
Table 6. China Biosimilar Monoclonal Antibodies Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Biosimilar Monoclonal Antibodies Price (2016-2021) & (USD/Unit)
Table 8. Manufacturers Biosimilar Monoclonal Antibodies Product Type
Table 9. List of Tier 1 Biosimilar Monoclonal Antibodies Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Biosimilar Monoclonal Antibodies Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Infliximab
Table 12. Major Manufacturers of Rituximab
Table 13. By Type - China Biosimilar Monoclonal Antibodies Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - China Biosimilar Monoclonal Antibodies Revenue (US$, Mn), 2016-2021
Table 15. By Type - China Biosimilar Monoclonal Antibodies Revenue (US$, Mn), 2022-2027
Table 16. By Type - China Biosimilar Monoclonal Antibodies Sales (K Units), 2016-2021
Table 17. By Type - China Biosimilar Monoclonal Antibodies Sales (K Units), 2022-2027
Table 18. By Application - China Biosimilar Monoclonal Antibodies Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - China Biosimilar Monoclonal Antibodies Revenue (US$, Mn), 2016-2021
Table 20. By Application - China Biosimilar Monoclonal Antibodies Revenue (US$, Mn), 2022-2027
Table 21. By Application - China Biosimilar Monoclonal Antibodies Sales (K Units), 2016-2021
Table 22. By Application - China Biosimilar Monoclonal Antibodies Sales (K Units), 2022-2027
Table 23. Celltrion Corporation Information
Table 24. Celltrion Description and Major Businesses
Table 25. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 26. Celltrion Biosimilar Monoclonal Antibodies Product
Table 27. Celltrion Recent Developments
Table 28. Pfizer (Hospira) Corporation Information
Table 29. Pfizer (Hospira) Description and Major Businesses
Table 30. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 31. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product
Table 32. Pfizer (Hospira) Recent Developments
Table 33. 3SBIO Corporation Information
Table 34. 3SBIO Description and Major Businesses
Table 35. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 36. 3SBIO Biosimilar Monoclonal Antibodies Product
Table 37. 3SBIO Recent Developments
Table 38. Novartis (Sandoz) Corporation Information
Table 39. Novartis (Sandoz) Description and Major Businesses
Table 40. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 41. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product
Table 42. Novartis (Sandoz) Recent Developments
Table 43. Dr Reddy's Corporation Information
Table 44. Dr Reddy's Description and Major Businesses
Table 45. Dr Reddy's Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 46. Dr Reddy's Biosimilar Monoclonal Antibodies Product
Table 47. Dr Reddy's Recent Developments
Table 48. Celgen Biopharma Corporation Information
Table 49. Celgen Biopharma Description and Major Businesses
Table 50. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 51. Celgen Biopharma Biosimilar Monoclonal Antibodies Product
Table 52. Celgen Biopharma Recent Developments
Table 53. Cadila Healthcare Corporation Information
Table 54. Cadila Healthcare Description and Major Businesses
Table 55. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 56. Cadila Healthcare Biosimilar Monoclonal Antibodies Product
Table 57. Cadila Healthcare Recent Developments
Table 58. Hisun Pharma Corporation Information
Table 59. Hisun Pharma Description and Major Businesses
Table 60. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 61. Hisun Pharma Biosimilar Monoclonal Antibodies Product
Table 62. Hisun Pharma Recent Developments
Table 63. Torrent Pharmaceuticals Corporation Information
Table 64. Torrent Pharmaceuticals Description and Major Businesses
Table 65. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 66. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product
Table 67. Torrent Pharmaceuticals Recent Developments
Table 68. Biosimilar Monoclonal Antibodies Production Capacity (K Units) of Key Manufacturers in China Market, 2019-2021 (K Units)
Table 69. China Biosimilar Monoclonal Antibodies Capacity Market Share of Key Manufacturers, 2019-2021
Table 70. Biosimilar Monoclonal Antibodies Market Opportunities & Trends in China Market
Table 71. Biosimilar Monoclonal Antibodies Market Drivers in China Market
Table 72. Biosimilar Monoclonal Antibodies Market Restraints in China Market
Table 73. Biosimilar Monoclonal Antibodies Raw Materials
Table 74. Biosimilar Monoclonal Antibodies Raw Materials Suppliers in China Market
Table 75. Typical Biosimilar Monoclonal Antibodies Downstream
Table 76. Biosimilar Monoclonal Antibodies Downstream Clients in China Market
Table 77. Biosimilar Monoclonal Antibodies Distributors and Sales Agents in China Market
List of FiguresFigure 1. Biosimilar Monoclonal Antibodies Product Picture
Figure 2. Biosimilar Monoclonal Antibodies Segment by Type
Figure 3. Biosimilar Monoclonal Antibodies Segment by Application
Figure 4. China Biosimilar Monoclonal Antibodies Market Overview: 2020
Figure 5. China Biosimilar Monoclonal Antibodies Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. China Biosimilar Monoclonal Antibodies Revenue, 2016-2027 (US$, Mn)
Figure 7. Biosimilar Monoclonal Antibodies Sales in China Market: 2016-2027 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Biosimilar Monoclonal Antibodies Revenue in 2020
Figure 9. Infliximab Product Picture
Figure 10. Rituximab Product Picture
Figure 11. Trastuzumab Product Picture
Figure 12. Adalimumab Product Picture
Figure 13. Other Product Picture
Figure 14. By Type - China Biosimilar Monoclonal Antibodies Sales Market Share, 2016-2027
Figure 15. By Type - China Biosimilar Monoclonal Antibodies Revenue Market Share, 2016-2027
Figure 16. By Type - China Biosimilar Monoclonal Antibodies Price (USD/Unit), 2016-2027
Figure 17. Oncology
Figure 18. Autoimmune Disease
Figure 19. Other
Figure 20. By Application - China Biosimilar Monoclonal Antibodies Sales Market Share, 2016-2027
Figure 21. By Application - China Biosimilar Monoclonal Antibodies Revenue Market Share, 2016-2027
Figure 22. By Application - China Biosimilar Monoclonal Antibodies Price (USD/Unit), 2016-2027
Figure 23. Celltrion Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. 3SBIO Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. Dr Reddy's Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. Celgen Biopharma Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Cadila Healthcare Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. Hisun Pharma Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. China Biosimilar Monoclonal Antibodies Production Capacity (K Units), 2016-2027
Figure 33. Biosimilar Monoclonal Antibodies Industry Value Chain
Figure 34. Marketing Channels